Mergers & Acquisitions ·
Beacon Topco, Inc. filed a Current Report on Form 8-K disclosing the Second Amendment to its Merger Agreement with…
CLYDBeacon Topco, Inc.
Beacon Topco, Inc. filed a Current Report on Form 8-K disclosing the Second Amendment to its Merger Agreement with Clywedog Therapeutics, Inc., which extends the closing date for the combination transaction to October 31, 2026. The filing also incorporates a joint press release announcing final results from Clywedog's Phase 1b study of balomenib in Type 2 Diabetes patients, showing sustained glycemic improvement and no serious adverse events. Beacon Topco operates as a holding company for biopharmaceutical assets.